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Background: Sleep quality is often poor in patients with chronic obstructive pulmonary 
disease (COPD). A cross-sectional European survey investigated the prevalence of night-time 
symptoms in COPD to evaluate the level of disconnect between physician and patient percep-
tions of the presence of night-time symptoms, and to compare the characteristics of patients 
with and without night-time symptoms.
Methods: A total of 251 primary care physicians and 251 respiratory specialists completed 
record forms on 2,807 patients with COPD. The forms captured information on patient demo-
graphics, lung function, COPD severity, and symptoms. Patients completed questionnaires 
on the time of day when their COPD symptoms bothered them, and the impact of COPD on 
their ability to get up in the morning and on sleep. Data were compared between groups (those 
with and without night-time symptoms) using t-tests or Wilcoxon signed rank tests. The kappa 
statistic was used to assess the level of disconnect between physician and patient perceptions 
of the impact of night-time symptoms.
Results: Most patients (78%) reported night-time disturbance. Patients with night-time symp-
toms experienced more daytime breathlessness (mean modified Medical Research Council 
dyspnea scale score 2.4 versus 1.1) and exacerbations in the previous 12 months (mean 1.7 
versus 0.4), and received more maintenance therapy (mean of 2.8 versus 2.3 products) than 
those without. Concordance between the frequency of physician-reported (67.9% of patients) 
and patient-reported (68.5% of patients) night-time symptoms was good. Physicians significantly 
underestimated the impact of COPD on the patient’s ability to get up in the morning and on 
sleep (fair–moderate agreement). Physician-reported night-time symptoms were present for 
41.2% of patients who could be categorized by Global initiative for chronic Obstructive Lung 
Disease (GOLD) group (n=937), increasing from 20.9% of those in the low-risk group to 77.4% 
of those in the high-riskgroup.
Conclusion: Patients with COPD experience night-time symptoms regardless of GOLD group, 
that impact on their ability to get up in the morning and on their sleep quality.
Keywords: chronic obstructive pulmonary disease, night-time symptoms, sleep quality, 
burden
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condi-
tion characterized by chronic airflow obstruction that is not fully reversible.1 Sleep 
quality is often poor in patients with COPD, and patients frequently report difficulty 
in falling asleep, nocturnal awakening, and insomnia.2,3 Epidemiological data sug-
gest that as many as 76% of patients may experience frequent nocturnal awakening.2,4 
Compared with individuals without COPD matched for age, sex, and body mass 
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index, patients with stable mild to moderate COPD appear 
to be more likely to report insomnia as well as difficulty 
in initiating and maintaining sleep.2 Poor sleep quality has 
been associated with a reduced quality of life in patients 
with COPD.5,6
Despite the apparent prevalence of poor sleep quality and 
sleep disturbance in patients with COPD, the contribution 
of COPD-related night-time symptoms has not been widely 
evaluated. Indeed, there is no formal definition of night-time 
symptoms in COPD.4
The potential long-term adverse consequences of sleep 
deprivation on human health are well documented and may 
include an increased risk of cardiovascular disease and 
all-cause mortality as well as depression.7–9 As such, night-
time symptoms and the associated sleep disturbance and 
deprivation have the potential to impact a range of long-term 
outcomes for patients with COPD.4–6
Understanding the impact of COPD symptoms on sleep 
quality and disturbance should enhance the ability of physi-
cians to manage and relieve the symptoms of the disease 
and potentially improve long-term outcomes for patients 
with COPD. The objectives of the current analysis were to 
evaluate the incidence of COPD-related night-time symp-
toms as reported by physicians and patients with COPD, 
and to test the hypothesis that the prevalence and impact of 
COPD-related night-time symptoms increase with increasing 
COPD severity. The analysis also sought to evaluate the level 
of disconnect between physician and patient perceptions of 
the presence of night-time symptoms, and to compare the 
characteristics of patients, including their Global initiative for 
chronic Obstructive Lung Disease (GOLD) grouping, with 
and without physician-reported night-time symptoms in order 
to explore the additional burden of night-time symptoms in 
patients with COPD.
Materials and methods
Data were drawn from the Adelphi Respiratory Disease 
 Specific Programme,10 a real-life, patient record-based sur-
vey of respiratory specialists and primary care physicians 
in France, Germany, Italy, Spain, and the UK conducted 
between June and September 2009.
The Respiratory Disease Specific Programme survey 
adhered to version 6.3 of the European Pharmaceutical 
Market Research Association (EphMRA) code of conduct 
governing market research, including the guidance related 
to collecting written informed consent from all participat-
ing patients and the anonymous and aggregated reporting 
of data.11 To ensure compliance with data protection laws, 
all data were deidentified and aggregated prior to receipt by 
Adelphi Real World.
Data collection
Physicians eligible to participate included respiratory spe-
cialists and primary care physicians caring for patients with 
COPD who were personally responsible for decisions about 
their treatment. In addition, physicians were required to see 
at least three patients with COPD each week.
Eligible physicians provided information on six consecu-
tive patients with COPD (aged .40 years with a history of 
smoking and a diagnosis of airflow obstruction). Information 
was collected via a physician record form. Physician-reported 
data included patient demographics, most recent forced 
respiratory volume over one second (FEV
1
), physician subjec-
tive severity assessment of COPD, exacerbation frequency 
in the last 12 months, and the modified Medical Research 
Council (mMRC) dyspnea scale score.1 Additional informa-
tion included the time of day the patient is most commonly 
bothered by their COPD overall (daytime only, night-time 
only, primarily daytime with occasional night-time, primarily 
night-time with occasional daytime, or both day and night), 
the time of day of individual COPD symptoms (daytime, 
night-time, and/or getting up in the morning), the impact 
of night-time symptoms on sleep (evaluated using a seven-
point Likert scale [1=no impact, 7=constant impact]), and the 
frequency of nocturnal awakening due to COPD symptoms 
(not at all, once or twice a week, once a week, 2–3 nights a 
week, or $4 nights a week).
Patients for whom a physician record form had been 
completed were then invited to voluntarily complete a self-
report questionnaire. Patient-reported data included the time 
of day the patient is bothered by their COPD (daytime only, 
night-time only, primarily daytime with occasional night-
time, primarily night-time with occasional daytime, or both 
day and night), the impact of COPD on the patient’s ability 
to get up in the morning and on sleep using a seven-point 
Likert scale (1=no impact, 7=constant impact), the Jenkins 
Sleep Questionnaire,12 the frequency of nocturnal awaken-
ing in the last 4 weeks due to COPD symptoms (not at all, 
once or twice a week, once a week, 2–3 nights a week, or 
$4 nights a week), the mMRC, and health-related quality 
of life using the EuroQol 5 dimensions measure (EQ-5D).13 
Patients completed the self-report questionnaire indepen-
dently and returned it to their physician in a sealed envelope, 
which was then returned unopened to the study coordinator. 
All responses were voluntary and anonymous to preserve 
patient confidentiality. Elements of the questionnaire that 
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did not form part of the validated tools were developed in 
English and then translated into the relevant language by 
native speakers. Subsequently, an independent UK translation 
agency performed a validation before approval.
statistical analyses
Demographic and disease characteristics were compared 
between groups (those with and without physician-reported 
night-time symptoms) using t-tests or Wilcoxon signed rank 
tests. The kappa statistic level of agreement was used to 
assess the level of disconnect between physician and patient 
 perceptions of the impact of night-time symptoms according to 
Landis and Koch, as follows:14 ,0.00 poor; 0.00–0.20 slight; 
0.21–0.40 fair; 0.41–0.60 moderate; 0.61–0.80 substantial; 
0.81–1.00 almost perfect.
Cohorts were selected on the basis of availability of 
responses to particular questions. Where a response was 
not available, the patient was excluded from that particular 
analysis.
Double-robust estimates15,16 of the effect of night-time 
disturbances on a variety of health-related and resource use-
related factors were computed. This method enables efficient 
adjustment for potential confounding factors. The confound-
ing factors used here were drawn from the physician report 
form and included age, sex, body mass index (calculated from 
height and weight), smoking status (current or ex-smoker), 
physician subjective assessment of COPD severity, presence 
of depression or anxiety, and physician-reported medication 
compliance (frequency per day). Compliance was defined as 
the extent to which patients, as assessed by their physician, 
followed their prescribing instructions and advice with regard 
to dosing frequency and inhaler device usage on a five-point 
Likert scale from “not at all compliant” to “fully compliant”. 
The method involves generating a propensity score based 
on the confounding factors (predicted values from a logistic 
regression for night-time disturbances). The inverse of this 
propensity score is then used in appropriate regressions on a 
given outcome, which also includes the confounding factors 
as covariates. The double-robust estimate is calculated from 
the results of these regressions, and shows how each outcome 
differs between patients with night-time disturbances and 
those with no night-time disturbance, having adjusted for 
confounding factors.
As per the GOLD 2013 strategy document, patients for 
whom an mMRC score (patient-reported) and either an FEV
1
 
score or exacerbation history (physician-reported), or both, 
were available were stratified by GOLD groups A–D.1 A valid 
FEV
1
 measurement was available for almost 50% of patients 
permitting full GOLD grouping; for the remaining patients 
GOLD grouping was by exacerbations only. The proportion 
of patients with and without night-time symptoms in each 
GOLD category was determined.
Results
A total of 251 primary care physicians and 251 respira-
tory specialists provided information on 2,807 patients. 
Table 1 provides an overview of the demographics and 
disease characteristics of the patient population. The cohort 
of patients for whom physician-only data were available 
tended to be slightly older, had a slightly lower mean FEV
1
, 
and were slightly more breathless (all as reported by their 
physician) than the cohort of patients with both physician-
reported and patient-reported data (Table 1). Data were 
available to categorize 1,699 patients by GOLD group (a 
patient-reported mMRC score and either an FEV
1
 score 
or physician-reported exacerbation history). The majority 
of patients (66.3%) were classified as GOLD group A or 
B (low-risk).
Incidence of night-time symptoms
Night-time sleep disturbance was reported by 78% of patients 
(Jenkins Sleep Questionnaire score .1 reported in the last 
28 days). Figure 1 illustrates the proportion of patients reporting 
various types of sleep disturbance in the previous 28 days.
awareness of night-time symptoms  
by physicians
Agreement between physician-reporting and patient-
 reporting of night-time symptoms was evaluated in the 
subset of patients who completed a self-report questionnaire 
(n=1,777). In this subgroup, a similar proportion of patients 
reported the presence of night-time symptoms whether 
based on physician’s opinion (67.9%) or patient’s opinion 
(68.5%).
Figure 2 shows the time of day that COPD symptoms 
bothered patients, as reported by both the physicians and 
patients. There were no statistically significant differences 
between physician and patient reporting of the time of day 
COPD symptoms bothered patients.
night-time symptoms and COPD  
disease severity
Physicians reported the presence of night-time symptoms 
in 1,207/1,777 (67.9%) patients for whom both physician-
reported and patient-reported data were available. Patients 
with night-time symptoms (as reported by their physician) 
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Table 1 Demographic and disease characteristics
Characteristic All  
patients
n Patients with physician- 
reported and patient- 
reported dataf
n Patients with  
physician-reported  
data onlyg
n P-value
Mean age, years (sD) 65.7 (10.5) 2,807 65.0 (10.5) 1,885 67.0 (10.3) 922 ,0.0001a
sex, % male 69.9 2,792 71.6 1,875 66.4 917 0.0057b
Mean BMI, kg/m2 (sD) 26.3 (7.6) 2,690 26.7 (8.5) 1,825 25.6 (5.1) 865 0.0002a
ethnic origin, n (%) 2,785 1,866 919 0.0003c
 White/Caucasian 2,662 (95.6) 1,791 (96.0) 871 (94.8)
 afro-Caribbean 28 (1.0) 13 (0.7) 15 (1.6)
 asian (Indian subcontinent) 8 (0.3) 2 (0.1) 6 (0.7)
 asian (other) 17 (0.6) 8 (0.4) 9 (1.0)
 hispanic 58 (2.1) 47 (2.5) 11 (1.2)
 Other 12 (0.4) 5 (0.3) 7 (0.8)
smoking status, n (%) 2,654 1,755 899 0.8991b
 ex-smoker 1,648 (62.1) 1,088 (62.0) 560 (62.3)
 Current smoker 1,006 (37.9) 667 (38.0) 339 (37.7)
Mean FeV1 (% predicted) 58.4 (20.2) 1,431 60.3 (20.1) 915 54.9 (19.9) 516 ,0.0001a
gOlD group, n (%) 1,699 1,699 0
 a 712 (41.9) 712 (41.9)
 B 414 (24.4) 414 (24.4)
 C 191 (11.2) 191 (11.2)
 D 382 (22.5) 382 (22.5)
Mean mMrC score (sD) 1.68 (1.3) 2,774 1.58 (1.2) 1,859 1.87 (1.3) 915 ,0.0001a
mMrC level of breathlessness, n (%) 2,774 1,859 915 ,0.0001d
 Too breathless to leave the house 258 (9.3) 151 (8.1) 107 (11.7)
  stops for a breath after walking  
a few minutes, even on level ground
540 (19.5) 344 (18.5) 196 (21.4)
  Walks slower than most people  
of the same age
603 (21.7) 372 (20.0) 231 (25.3)
  gets breathless when hurrying  
on level ground or walking  
up a slight incline
796 (28.7) 566 (30.5) 230 (25.1)
  Only gets breathless after  
exercising heavily
577 (20.8) 426 (22.9) 151 (16.5)
Mean Jenkins sleep Questionnaire  
score (sD)
4.73 (4.6) 1,746 4.73 (4.6) 1,746 – 0 –a
Concomitant conditions,e n (%) 2,807 1,885 922
 elevated cholesterol 606 (21.6) 424 (22.5) 181 (19.6) 0.0950c
 hypertension 1,207 (43.0) 837 (44.4) 372 (40.3) 0.0540c
 Diabetes 340 (12.1) 226 (12.0) 114 (12.4) 0.8060c
 Prostate disorder 320 (11.4) 230 (12.2) 90 (9.8) 0.0580c
 anxiety 280 (10.0) 179 (9.5) 101 (11.0) 0.2280b
 Depression 361 (12.9) 222 (11.8) 139 (15.1) 0.0163b
Time of day of symptoms, n (%) 2,754 1,848 906 0.0130c
 Daytime only 901 (32.7) 587 (31.8) 314 (34.7)
  Primarily daytime with  
occasional night time
1,021 (37.1) 704 (38.1) 317 (35.0)
  Both day and night 670 (24.3) 432 (23.4) 238 (26.3)
  Primarily night time with  
occasional daytime
115 (4.2) 89 (4.8) 26 (2.9)
  night time only 47 (1.7) 36 (2.0) 11 (1.2)
respiratory drug therapy, n (%) 2,807 1,885 922 ,0.0001c
 saBa only 200 (7.1) 133 (7.1) 67 (7.3)
 laBa 99 (3.5) 81 (4.3) 18 (2.0)
 laMa 540 (19.2) 390 (20.7) 150 (16.3)
 ICs 87 (3.1) 60 (3.2) 27 (2.9)
 ICs/laBa 701 (25.0) 488 (25.9) 213 (23.1)
 ICs/laMa 45 (1.6) 28 (1.5) 17 (1.8)
(Continued)
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Figure 1 Proportion of patients reporting the four types of sleep disturbance in the previous 28 days as defined by the Jenkins Sleep Questionnaire.
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Patient-reported (N=1777)
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Night time only
Primarily night time with occasional day
Both day and night
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Figure 2 Time of day that the patient’s COPD symptoms bother them, as reported by physicians and the patients themselves (the analysis set was the cohort for whom 
both physician-reported and patient-reported data were available).
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 1 (Continued)
Characteristic All  
patients
n Patients with physician- 
reported and patient- 
reported dataf
n Patients with  
physician-reported  
data onlyg
n P-value
 laBa/laMa 104 (3.7) 83 (4.4) 21 (2.3)
 ICs/laBa/laMa 911 (32.5) 544 (28.9) 367 (39.8)
 Other 120 (4.3) 78 (4.1) 42 (4.6)
Notes: at-test; bFisher’s exact test; cchi-square test; dMann–Whitney; ePhysician-confirmed diagnosis; fPhysician report Form and Patient self-Completion Questionnaire 
available; gPhysician report Form only available.
Abbreviations: BMI, body mass index; FeV1, forced respiratory volume over one second; gOlD, global initiative for chronic Obstructive Disease; ICs, inhaled corticosteroid; 
LABA, long-acting bronchodilator; LAMA, long-acting antimuscarinic agent; mMRC, modified Medical Research Council; SABA, short-acting bronchodilator; SD, standard 
deviation.
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Table 2 Characteristics of patients with and without physician-reported night time symptoms
Characteristic With NTSe Without NTSf P-value
Mean age, years 67.6
n=670g
64.3
n=901
sex, n (%) malea 462 (69.2) 621 (69.2) 1.0
smoking status, n (%)a
 ex-smoker
 Current smoker
401 (61.7)
249 (38.3)
509 (59.7)
344 (40.3)
0.456
Mean FeV1 % predicted
b 49.4
n=320
64.1
n=499
,0.0001
gOlD group, n (%)c
 a
 B
 C
 D
92 (20.9)
100 (45.9)
43 (50.6)
151 (77.4)
347 (79.0)
118 (54.1)
42 (49.4)
44 (22.6)
,0.0001
Mean mMrC score (sD)b 2.4
n=662
1.1
n=891
,0.0001
level of breathlessness (mMrC), n (%)d
  Too breathless to leave the house
  stops for a breath after walking a few minutes
  Walks slower than most people of the same age
  gets breathless when hurrying on level ground
  Only gets breathless after exercising heavily
n=662
147 (22.2)
189 (28.5)
150 (22.7)
121 (18.3)
55 (8.3)
n=891
15 (1.7)
87 (9.8)
183 (20.5) 
301 (33.8)
305 (34.2)
,0.0001
Mean eQ-5D (patient-reported) 0.59
n=400
0.82
n=561
,0.0001
number of exacerbations in the last 12 months, mean (sD) 1.69 (2.37)
n=604
0.41 (0.86)
n=869
–
Mean number of maintenance products for COPDd 2.8
n=670
2.3
n=901
,0.0001
Visits to physician in the last 12 months, mean (sD) 6.19
n=665
3.88
n=897
,0.0001
hospital admissions, mean (sD) 0.48
n=641
0.08
n=850
,0.0001
emergency department admissions, mean (sD) 0.48
n=642
0.08
n=850
,0.0001
ICU admissions, mean (sD) 0.07
n=642
0.01
n=850
,0.0001
number of nights spent in ICU, mean (sD) 0.29
n=641
0.02
n=848
,0.0001
number of nights spent in hospital, mean (sD) 3.47
n=637
0.48
n=850
,0.0001
Notes: aFisher’s exact test; bt-test; cchi-square test; dMann–Whitney; ephysician-reported both daytime and night-time symptoms (excluding patients for whom occasional 
daytime or night-time symptoms were reported and those with night-time symptoms only); fphysician-reported daytime symptoms only; gn values refer to the number of 
patients for whom a response to the relevant question was available.
Abbreviations: COPD, chronic obstructive pulmonary disease; eQ-5D, euroQol 5 dimensions measure; FeV1, forced respiratory volume over one second; gOlD, global 
initiative for chronic Obstructive Disease; ICU, intensive care unit; mMRC, modified Medical Research Council; NTS, night-time symptoms; SD, standard deviation.
experienced more daytime breathlessness and exacerbations 
in the previous 12 months (both physician-reported), and 
received more maintenance therapy (physician-reported) 
compared with patients classified as having daytime only 
symptoms (Table 2).
Information was available to categorize a total of 
1,699 patients by GOLD group; of these, data on the presence 
or absence of night-time symptoms were available for 937 
(for the remaining patients physician-reported information 
on the presence of night-time symptoms were not available). 
Physicians reported the presence of night-time symptoms in 
386/937 patients (41.2%), 192 of whom (50%) were assigned 
to the low-risk groups (A and B) and 194 (50%) were 
assigned to one of the two high-risk groups (C and D).
association between night-time 
symptoms and sleep and health status  
in patients with COPD
Patients whose physician reported that they experienced 
night-time symptoms were significantly more likely to 
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Table 3 association of night-time symptoms and health and resource use-related factors
Factor Observations Coefficient 95% CI P-value
Jenkins sleep Questionnaire 829 3.493 2.778–4.207 ,0.0001
symptoms when getting up in the morning 880 0.237 0.165–0.309 ,0.0001
eQ-5D state valuation 842 –0.101 -0.138 to -0.064 ,0.0001
mMrC dyspnea scale 871 0.446 0.582–0.310 ,0.0001
number of physician visits 876 2.518 1.825–3.211 ,0.0001
number of hospital admissions 834 0.187 0.114–0.261 ,0.0001
number of emergency department admissions 834 0.216 0.151–0.281 ,0.0001
number of ICU admissions 834 0.034 0.009–0.059 0.009
number of nights in ICU 834 0.130 0.037–0.222 0.006
number of nights in hospital 832 1.277 0.640–1.913 ,0.0001
number of maintenance products currently prescribed 880 0.189 0.080–0.298 ,0.001
Abbreviations: CI, confidence interval; EQ-5D, EuroQol 5 dimensions measure; ICU, intensive care unit; mMRC, modified Medical Research Council.
experience COPD-related symptoms when getting up in the 
morning (as reported by their physician) than those whose 
physician reported that they did not experience night-time 
symptoms (52.4% versus 19.2%, respectively; P,0.001). 
They were also more likely to self-report at least some level of 
sleep disturbance (Jenkins Sleep Questionnaire) in the previ-
ous 28 days compared with those without physician-reported 
night-time symptoms (91.1% versus 60.5%; P,0.0001). 
Patients with physician-reported night-time symptoms had 
significantly poorer health-related quality of life (as assessed 
using the EQ-5D) compared with those without physician-
reported night-time symptoms (mean scores 0.59 and 0.82, 
respectively) and significantly higher health care resource 
utilization (P,0.0001, Table 2).
Multivariate regression analysis of the association 
between night-time symptoms and measures of health sta-
tus and resource use (Table 3) demonstrated a significant 
association (P,0.0001) between night-time symptoms and 
a variety of health status-related and resource use-related 
factors when patients with and without physician-reported 
night-time symptoms were compared. Thus, the presence of 
night-time symptoms was associated with higher scores on 
the Jenkins Sleep Questionnaire and mMRC dyspnea scale 
(coefficients of 3.493 and 0.446, respectively), the presence 
of symptoms when getting up in the morning (coefficient 
0.237), a lower EQ-5D state valuation (coefficient –0.101), 
and increased health care resource utilization, including 
number of physician visits (coefficient 2.518) and hospital 
admissions (coefficient 0.187).
Impact of COPD on lifestyle factors
The difference between physician and patient perception 
of the impact of COPD was statistically significant for the 
impact on the patients’ ability to get up in the morning 
(mean scores 3.05 and 3.12, respectively, P=0.018) and for 
the impact on sleep (mean scores 2.84 and 3.02, respec-
tively, P,0.0001, Figure 3). The difference in perception 
of the impact of COPD was of borderline significance for 
the patient’s ability to complete their normal daily activities 
(mean scores 3.38 and 3.44, respectively, P=0.0535). The 
level of agreement (kappa statistic) across the lifestyle factors 
evaluated was regarded as fair to moderate.
Discussion
In this cohort of more than 2,800 patients with COPD, the 
majority reported some degree of sleep disturbance in the 
previous 28 days, including trouble falling asleep, waking 
up during the night, trouble staying asleep, and waking up 
feeling worn out after a usual amount of sleep.
Physicians reported that their patients experienced a 
variety of COPD-related symptoms both during the night and 
on waking in the morning, and that the majority of patients 
(67.3%) experienced night-time symptoms. When the patient 
cohort was stratified for the presence of night-time symp-
toms, those with nocturnal symptoms also experienced more 
daytime breathlessness and more frequent exacerbations, 
and used more maintenance products than those without 
night-time symptoms. Moreover, patients with night-time 
symptoms appeared to be more likely to experience difficulty 
in getting up in the morning, disturbed sleep, and poorer 
quality of life.
There appeared to be a good level of concordance between 
the frequency of physician-reported and patient- reported 
night-time symptoms. However, physicians appeared to sig-
nificantly underestimate the impact of COPD on the ability 
of patients to get up in the morning and on sleep. A survey 
of more than 800 patients with COPD in Europe and the 
US revealed a range of activities that were impacted by the 
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Mean scorea (Likert scale 1 [no impact] to 7 [constant impact])
10
Sleep (N=1,769)
Patient Physician
Caregiver’s mood (N=1,192)
Work (N=1,384)
Getting up in the morning (N=1,764)
Normal daily activities (N=1,798)
Leisure/personal time (N=1,759)
Personal relationships (N=1,743)
Patient’s mood (N=1,757)
Difference −0.18
(t-test P=0.0000; kappa 0.560)
Difference −0.08
(t-test P=0.1356; kappa 0.2036)
Difference −0.08
(t-test P=0.0533; kappa 0.3372)
Difference −0.07
(t-test P=0.0180; kappa 0.5979)
Difference −0.06
(t-test P=0.0535; kappa 0.5612)
Difference −0.05
(t-test P=0.1140; kappa 0.5416)
Difference −0.04
(t-test P=0.2160; kappa 0.5321)
Difference −0.03
(t-test P=0.3880; kappa 0.5200)
Figure 3 Impact of COPD on lifestyle factors, as assessed by patients and their physicians (the analysis set was the cohort for whom both physician-reported and patient-
reported data were available).
Note: aPatients and physicians were asked to rate the impact of COPD on various lifestyle factors on a seven-point likert scale (1=no impact, 7=constant impact).
Abbreviation: COPD, chronic obstructive pulmonary disease.
disease in the mornings, including the ability to walk up 
and down stairs, washing and personal hygiene, and getting 
dressed.17 A more directed approach to relieving or improv-
ing sleep quality and quantity by addressing night-time 
symptoms may be of particular benefit to patients in reducing 
how bothersome the disease is perceived to be. A number of 
recent studies have highlighted the high symptom burden and 
significant impact on global quality of life for patients with 
COPD, a burden which has been estimated to be comparable 
with that of patients with cancer.18,19
The strengths of the study reported here include the large 
cohort of patients (.2,800) and the collection of data from 
both the physician’s and patient’s perspective. A number 
of the analyses presented here required comparison of both 
physician-reported and patient-reported data and so were 
conducted in the subgroup of patients for whom such data 
were available (n=1,777). A comparison of the baseline 
demographic and disease characteristics in this subgroup 
with the cohort of patients having only physician-reported 
data revealed that patients for whom physician-only data 
was available tended to be slightly older, had a slightly 
lower mean FEV
1
, and were slightly more breathless (all as 
reported by their physician) than the cohort of patients with 
both physician-reported and patient-reported data. Although 
these differences reached statistical significance, the absolute 
differences were small and, in the opinion of the authors, are 
unlikely to bias the conclusions presented here. Multivariate 
techniques were also employed to take into consideration a 
number of confounders (Table 3). The study is limited by 
the collection of data only from patients presenting for care 
(primary or specialist). As such, this cohort of patients may 
represent those more bothered by their symptoms at the time 
of the study. The cross-sectional nature of the data also limits 
the conclusions that can be drawn from the data presented here 
to an observed association rather than a causal relationship, 
particularly given that a number of analyses were conducted 
in subgroups of patients where both physician-reported and 
patient-reported data were available. Finally, the data must be 
viewed with caution given that it was not possible to adjust the 
data in order to account fully for the contribution of disease 
severity to the observations reported here.
The results of this retrospective analysis of a large 
cohort of patients with COPD have demonstrated a high 
prevalence of sleep disturbance and a high frequency of 
nocturnal COPD-related symptoms. The prevalence of night-
time symptoms appears to increase with increasing disease 
severity. However, our study suggests that even patients 
who meet the criteria for GOLD categories A and B report a 
considerable amount of night-time symptoms. Patients report 
a considerable impact of COPD on their ability to get up in 
the morning and their sleep. These results indicate a need 
to increase the awareness of the impact of COPD symptoms 
on sleep and to specifically address the burden of night-time 
symptoms and early morning symptoms in patients with 
COPD. Identifying patients with night-time and early morn-
ing symptoms would allow physicians to tailor treatment to 
address this unmet need with the aim of improving patient 
quality of life and health status.
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